Oral ponesimod in patients with chronic plaque psoriasis: A randomised, double-blind, placebo-controlled phase 2 trial

The Lancet

Volumn 384, Issue 9959, 2014, Pages 2036-2045

  Vaclavkova, Andrea ^a   Chimenti, Sergio ^b   Arenberger, Petr ^c   Holló, Peter ^d   Sator, Paul Gunther ^e   Burcklen, Michel ^a   Stefani, Mylène ^a   D'Ambrosio, Daniele ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c CHARLES UNIVERSITY   (Czech Republic)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e Department of Dermatology   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIVER ENZYME; PLACEBO; PONESIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THIAZOLE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BRADYCARDIA; CHRONIC DISEASE; CONTROLLED STUDY; COUGHING; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART DISEASE; HODGKIN DISEASE; HUMAN; MACULAR EDEMA; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPPORTUNISTIC INFECTION; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRURITUS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SINUS BRADYCARDIA; SYSTEMATIC REVIEW; TOXIC HEPATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; ORAL DRUG ADMINISTRATION; PSORIASIS;

ADMINISTRATION, ORAL; CHRONIC DISEASE; DOUBLE-BLIND METHOD; HUMANS; PSORIASIS; THIAZOLES; TREATMENT OUTCOME;

EID: 84919839734     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60803-5     Document Type: Article

References (33)

1. FO Nestle, DH Kaplan, J Barker Psoriasis N Engl J Med 361 2009 496 509
2. SR Rapp, SR Feldman, ML Exum, AB Fleischer Jr, DM Reboussin Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 41 1999 401 407
3. C Paul, A Gallini, E Archier et al. Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists J Eur Acad Dermatol Venereol 26 suppl 3 2012 1 10
4. MH Rustin Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data Br J Dermatol 167 suppl 3 2012 3 11
5. V Brinkmann, MD Davis, CE Heise et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors J Biol Chem 277 2002 21453 21457
6. MH Bolli, S Abele, C Binkert et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists J Med Chem 53 2010 4198 4211
7. LM Gatfield, L Monnier, R Studer, MH Bolli, B Steiner, O Nayler Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling Cell Signal 26 2014 1576 1588
8. P Brossard, H Derendorf, J Xu, H Maatouk, A Halabi, J Dingemanse Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study Br J Clin Pharmacol 76 2013 888 896
9. P Brossard, M Scherz, A Halabi, H Maatouk, A Krause, J Dingemanse Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration J Clin Pharmacol 2014 10.1002/jcph.244 published online Jan 9.
10. K Papp, JC Cather, L Rosoph et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial Lancet 380 2012 738 746
11. KA Papp, A Menter, B Strober et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study Br J Dermatol 167 2012 668 677
12. L Piali, S Froidevaux, P Hess et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation J Pharmacol Exp Ther 337 2011 547 556
13. L Kappos, J Antel, G Comi for the FTY720 D2201 Study Group Oral fingolimod (FTY720) for relapsing multiple sclerosis N Engl J Med 355 2006 1124 1140
14. T Olsson, A Boster, A Fernandez et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial J Neurol Neurosurg 2014 10.1136/jnnp-2013-307282 published online April 8.
15. EMEA Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003329.pdf (accessed July 8, 2014).
16. AY Finlay, GK Khan Dermatology life quality index (DLQI) - a simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216
17. JE Ware Jr, M Kosiniski, JB Bjorner et al. User's manual for the SF-36v2™ Health Survey 2nd edn 2007 Quality Metric Inc Lincoln, RI
18. D Pathirana, AD Ormerod, P Saiag et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris J Eur Acad Dermatol Venereol 23 suppl 2 2009 1 70
19. S Bremmer, AS Van Voorhees, S Hsu the National Psoriasis Foundation Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation J Am Acad Dermatol 63 2010 1058 1069
20. L Clark, M Lebwohl The effect of weight on the efficacy of biologic therapy in patients with psoriasis J Am Acad Dermatol 58 2008 443 446
21. A Bewley, DM Burrage, SJ Ersser, M Hansen, C Ward Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study J Eur Acad Dermatol Venereol 28 2014 763 770
22. LM Johnson-Huang, MA Lowes, JG Krueger Putting together the psoriasis puzzle: an update on developing targeted therapies Dis Model Mech 5 2012 423 433
23. Pozzilli C, Fernandez O, Olsson T, et al. Maintenance of efficacy, safety and tolerability of ponesimod in patients with relapsing-remitting multiple sclerosis: phase II extension study. 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) and the 18th Annual Conference of Rehabilitation in MS (RIMS); Copenhagen, Denmark; Oct 4, 2013. Abstr P995.
24. C Pouplard, E Brenaut, C Horreau et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies J Eur Acad Dermatol Venereol 27 suppl 3 2013 36 46
25. JM Gelfand, DB Shin, AL Neimann, X Wang, DJ Margolis, AB Troxel The risk of lymphoma in patients with psoriasis J Invest Dermatol 126 2006 2194 2201
26. D Pelletier, DA Hafler Fingolimod for multiple sclerosis N Engl J Med 366 2012 339 347
27. P Gergely, B Nuesslein-Hildesheim, D Guerini et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate Br J Pharmacol 167 2012 1035 1047
28. SL Peters, AE Alewijnse Sphingosine-1-phosphate signaling in the cardiovascular system Curr Opin Pharmacol 7 2007 186 192
29. M Rey, P Hess, M Clozel et al. Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator PLoS One 8 2013 e74285
30. MG Sanna, SK Wang, PJ Gonzalez-Cabrera et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo Nat Chem Biol 2 2006 434 441
31. F Roviezzo, A Di Lorenzo, M Bucci et al. Sphingosine-1-phosphate/sphingosine kinase pathway is involved in mouse airway hyperresponsiveness Am J Respir Cell Mol Biol 36 2007 757 762
32. N Jain, MT Bhatti Fingolimod-associated macular edema: incidence, detection, and management Neurology 78 2012 672 680
33. J Hick, SR Feldman Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments J Am Acad Dermatol 57 2007 972 976